The BCL-2 gene was initially discovered because of its involvement in t(14;18) translocations that occur in the majority of follicular non- Hodgkin's lymphomas (NHLs), a common low-grade form of lymphoma which is nevertheless presently incurable. Since then, rearrangements of the BCL-2 gene dur to a t(14;18) or other chromosomal translocations have been detected in about 30% of aggressive NHLs. The protein encoded by BCL-2 is unique among oncogenes in that it resides in mitochondria and causes cell accumulation by decreasing the rate of cell death, rather than by increasing the rate of cell proliferation. Recent data indicate that BCL-2 overexpression blocks """"""""programmed cell death"""""""" (also termed, """"""""apoptosis""""""""), a mechanism of cellular demise that is induced by many chemotherapeutic drugs. Consequently, hematolymphoid cells containing activated BCL-2 genes are resistant to killing by many anti-cancer drugs and x-irradiation. Given that BCL-2 can increase cellular resistance to chemotherapeutic drugs, it seems likely that patients whose NHLs have deregulated BCL-2 expression may experience a worse clinical outcome than those with histologically similar tumors lacking activation of this oncogene. To test this hypothesis, we will evaluate BCL-2 gene structure and expression in biopsy specimens from patients enrolled in therapeutic trials sponsored by the Eastern Cooperative Oncology Group (ECOG). By evaluating the status of the BCL-2 gene in the setting of well-controlled clinical trials, we will be able to statistically assess the prognostic significance of BCL-2 for particular groups of NHL patients. PCR technology will also be applied to bone marrow and blood samples for detecting small numbers of t(14;18)- containing tumors cells; this information will be compared with routine histopathological methods for detection of disease and the data correlated with clinical outcome. Taken together, these molecular investigations of the BCL-2 gene in patients with NHLs will permit clinico-pathological correlations that may ultimately contribute to improved strategies for patient treatment.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA060421-02
Application #
2101160
Study Section
Special Emphasis Panel (SRC (51))
Project Start
1993-09-30
Project End
1997-09-29
Budget Start
1994-09-30
Budget End
1995-09-29
Support Year
2
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Sanford-Burnham Medical Research Institute
Department
Type
DUNS #
009214214
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Brousset, P; Krajewski, S; Schlaifer, D et al. (1999) Detection of the cell death-inducing protein BAK in Reed-Sternberg cells of Hodgkin's disease. Leuk Lymphoma 34:581-4
James, H J; Sharer, L R; Zhang, Q et al. (1999) Expression of caspase-3 in brains from paediatric patients with HIV-1 encephalitis. Neuropathol Appl Neurobiol 25:380-6
Reed, J C (1998) Molecular biology of chronic lymphocytic leukemia. Semin Oncol 25:11-8
Kitada, S; Andersen, J; Akar, S et al. (1998) Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses. Blood 91:3379-89
Gascoyne, R D; Adomat, S A; Krajewski, S et al. (1997) Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 90:244-51
Chhanabhai, M; Krajewski, S; Krajewska, M et al. (1997) Immunohistochemical analysis of interleukin-1beta-converting enzyme/Ced-3 family protease, CPP32/Yama/Caspase-3, in Hodgkin's disease. Blood 90:2451-5
Gascoyne, R D; Krajewska, M; Krajewski, S et al. (1997) Prognostic significance of Bax protein expression in diffuse aggressive non-Hodgkin's lymphoma. Blood 90:3173-8
Bullrich, F; Veronese, M L; Kitada, S et al. (1996) Minimal region of loss at 13q14 in B-cell chronic lymphocytic leukemia. Blood 88:3109-15
Branet, F; Brousset, P; Krajewski, S et al. (1996) Expression of the cell death-inducing gene bax in carcinomas developed from the follicular cells of the thyroid gland. J Clin Endocrinol Metab 81:2726-30
Schlaifer, D; Krajewski, S; Galoin, S et al. (1996) Immunodetection of apoptosis-regulating proteins in lymphomas from patients with and without human immunodeficiency virus infection. Am J Pathol 149:177-85

Showing the most recent 10 out of 17 publications